Case Studies & Method Reports

Come see why we’re excited about what we do and the future of AI-enabled drug development!

Finding the right patients, analogs, and indications for ONC201

ONC201 was a first-in-class anticancer compound in Phase II clinical trials, however its binding target and mechanism of action were unknown, which made future development and therapeutic positioning difficult. Our platform integrated data on ONC201’s structure, efficacy, and genomic effects to identify and validate its mechanism of action. Based on the identified binding target, we ranked other imipridone analogs based on predicted selectivity and efficacy, and identified the optimal cancer subtypes for Oncoceutics to pursue clinically. These predictions were validated in vitro, in vivo, and through clinical trials.


Discovery of Novel Microtubule Inhibitors for Resistant Cancers

ONC201 was a first-in-class anticancer compound in Phase II clinical trials, however its binding target and mechanism of action were unknown, which made future development and therapeutic positioning difficult. Our platform integrated data on ONC201’s structure, efficacy, and genomic effects to identify and validate its mechanism of action. Based on the identified binding target, we ranked other imipridone analogs based on predicted selectivity and efficacy, and identified the optimal cancer subtypes for Oncoceutics to pursue clinically. These predictions were validated in vitro, in vivo, and through clinical trials.

Predicting Genotype Specific Synergistic Combinations

ONC201 was a first-in-class anticancer compound in Phase II clinical trials, however its binding target and mechanism of action were unknown, which made future development and therapeutic positioning difficult. Our platform integrated data on ONC201’s structure, efficacy, and genomic effects to identify and validate its mechanism of action. Based on the identified binding target, we ranked other imipridone analogs based on predicted selectivity and efficacy, and identified the optimal cancer subtypes for Oncoceutics to pursue clinically. These predictions were validated in vitro, in vivo, and through clinical trials.

 


Discovery of Novel Microtubule Inhibitors for Resistant Cancers

ONC201 was a first-in-class anticancer compound in Phase II clinical trials, however its binding target and mechanism of action were unknown, which made future development and therapeutic positioning difficult. Our platform integrated data on ONC201’s structure, efficacy, and genomic effects to identify and validate its mechanism of action. Based on the identified binding target, we ranked other imipridone analogs based on predicted selectivity and efficacy, and identified the optimal cancer subtypes for Oncoceutics to pursue clinically. These predictions were validated in vitro, in vivo, and through clinical trials.